Skip to main content
. Author manuscript; available in PMC: 2019 Mar 26.
Published in final edited form as: Ocul Surf. 2018 Jul 7;16(4):463–469. doi: 10.1016/j.jtos.2018.07.004

Fig. 6.

Fig. 6.

Effect of PPARγ signaling on ADFP, PPARγ, ELOVL4 and FABP4 protein expression. (A, B) Western blotting showed that rosiglitazone upregulated ADFP, PPARγ, ELOVL4, and FABP4 protein expression in hMGEC and T0070907 significantly abrogated upregulation of these proteins induced by activation of PPARγ signaling when treated prior to rosiglitazone. (C–F) Bar graphs showed that rosiglitazone significantly upregulated expression of ADFP, PPARγ, ELOVL4, and FABP4 proteins by 2.8, 1.7, 1.6, and 1.9 folds on average (all P < 0.05), which were significantly decreased in cells treated with PPARγ antagonist T0070907 similar to control cells (n = 4).